Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
Heikki Kuusanmäki(University of Copenhagen), Caroline A. Heckman(University of Helsinki)
Cited by 31
Related Papers
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
|Haematologica|2019|184
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
|Blood|2022|123
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
|Blood|2017|122